首次覆盖专注于小分子肿瘤精准治疗，扭亏为盈迎来拐点

首次覆盖：专注于小分子肿瘤精准治疗，扭亏为盈迎来拐点 Focusing on Precision Therapy with Small Molecules in Oncology, Achieving Profitability and Reaching an Turning Point: Initiation [Table_yemei1] 观点聚焦 Investment Focus 研究报告 Research Report 14 May 2025 和誉-B Abbisko (2256 HK) [Table_Info] 首次覆盖优于大市 Initiate with OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$8.06 目标价 HK$13.40 HTI ESG 4.8-4.8-4.5 - -G: 0- , (Please refer to the Appendix for ESG comments) 市值 HK$5.48bn / US$0.70bn 日交易额 (3 个月均值) US$5.95mn 发行股票数目 680.11mn 自由流通股 (%) 67% 年股价最高最低值 HK$8. ...